SG11202003398SA - Adenovirus vectors and uses thereof - Google Patents
Adenovirus vectors and uses thereofInfo
- Publication number
- SG11202003398SA SG11202003398SA SG11202003398SA SG11202003398SA SG11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA
- Authority
- SG
- Singapore
- Prior art keywords
- adenovirus vectors
- adenovirus
- vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199350 | 2017-10-31 | ||
| PCT/EP2018/079719 WO2019086461A1 (en) | 2017-10-31 | 2018-10-30 | Adenovirus vectors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003398SA true SG11202003398SA (en) | 2020-05-28 |
Family
ID=60413038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003398SA SG11202003398SA (en) | 2017-10-31 | 2018-10-30 | Adenovirus vectors and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11459583B2 (en) |
| EP (1) | EP3704256A1 (en) |
| JP (1) | JP7229239B2 (en) |
| KR (1) | KR102755022B1 (en) |
| CN (1) | CN111295449B (en) |
| AU (1) | AU2018359494A1 (en) |
| BR (1) | BR112020008435A2 (en) |
| CA (1) | CA3077630A1 (en) |
| EA (1) | EA202091039A1 (en) |
| IL (1) | IL274218A (en) |
| MX (1) | MX421606B (en) |
| SG (1) | SG11202003398SA (en) |
| WO (1) | WO2019086461A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
| CN108064275A (en) | 2014-09-24 | 2018-05-22 | 萨克生物研究学院 | Oncolytic tumour virus and application method |
| ES2933174T3 (en) | 2016-02-23 | 2023-02-02 | Salk Inst For Biological Studi | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS DIRECTIVE TO TUMORS AND USES THEREOF |
| WO2018229711A1 (en) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| JP7430395B2 (en) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Oncolytic adenovirus compositions with enhanced replication characteristics |
| TW202204380A (en) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | Compositions and methods for preventing and treating coronavirus infection - sars-cov-2 vaccines |
| US20240189416A1 (en) | 2020-05-11 | 2024-06-13 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| BR112022026408A2 (en) | 2020-06-29 | 2023-01-17 | Janssen Vaccines & Prevention Bv | VACCINE COMBINATION AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION |
| JP2023532369A (en) | 2020-07-06 | 2023-07-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Stabilized coronavirus spike protein fusion protein |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| CN116802280B (en) * | 2021-01-21 | 2024-09-17 | 希力德株式会社 | Novel adenoviral vectors excluding replication-competent adenoviruses and their uses |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| MX2023009738A (en) | 2021-02-19 | 2023-08-30 | Janssen Vaccines & Prevention Bv | STABILIZED PRE-FUSION RSV F<sub>B</sub> ANTIGENS. |
| US20240197859A1 (en) | 2021-04-01 | 2024-06-20 | Janssen Vaccines & Prevention B.V. | Stabilized Pre-Fusion PIV3 F Proteins |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| CR20250116A (en) | 2022-10-06 | 2025-05-05 | Msd Int Business Gmbh | STABILIZED PREFUSION PIV3 PROTEIN F |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (en) | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| EP1548118A2 (en) | 1994-06-10 | 2005-06-29 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US6127525A (en) | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| IL122614A0 (en) | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
| JP2000509614A (en) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | Adenovirus E1-complementation cell line |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| CA2378539A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
| DE19955558C2 (en) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanent amniocyte cell line, its production and use for the production of gene transfer vectors |
| WO2002022080A2 (en) | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| KR20040043129A (en) | 2001-06-22 | 2004-05-22 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | Method of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| MXPA04008891A (en) | 2002-04-25 | 2004-11-26 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors. |
| CA2502268A1 (en) | 2002-10-23 | 2004-05-06 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
| CA2880060C (en) | 2004-01-23 | 2018-03-13 | Agostino Cirillo | Chimpanzee adenovirus vaccine carriers |
| ES2358523T3 (en) | 2004-10-13 | 2011-05-11 | Crucell Holland B.V. | IMPROVED ADENOVIRAL VECTORS AND USES OF THE SAME. |
| AP2351A (en) * | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| ES2607029T3 (en) | 2007-11-28 | 2017-03-28 | The Trustees Of The University Of Pennsylvania | Adenovirus comprising a hexon protein of the apex adenovirus E of simian SAdV-39 and uses thereof |
| WO2010060719A1 (en) | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| MX2011007980A (en) | 2009-02-02 | 2011-08-17 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof. |
| RU2012107702A (en) | 2009-07-31 | 2013-09-10 | Пэксвэкс, Инк. | ADENOVIRUS VECTORS |
| PL2536829T3 (en) | 2010-02-15 | 2016-09-30 | Method for the production of Ad26 adenoviral vectors | |
| ES2711613T3 (en) | 2010-04-16 | 2019-05-06 | Us Gov Health & Human Services | Filovirus vaccines based on an adenovirus chimpanzee vector |
| WO2013016591A1 (en) | 2011-07-26 | 2013-01-31 | Zuvachem, Inc. | High efficiency isoprene synthases produced by protein engineering |
| US9580476B2 (en) | 2011-10-05 | 2017-02-28 | Genvec, Inc. | Adenoviral vector-based respiratory syncytial virus (RSV) vaccine |
| EP2850194A4 (en) | 2012-05-18 | 2016-06-08 | Univ Pennsylvania | SIMILAR ADENOVIRUSES OF SUBHEAD E A1302, A1320, A1331 AND A1337 AND USES THEREOF |
-
2018
- 2018-10-30 SG SG11202003398SA patent/SG11202003398SA/en unknown
- 2018-10-30 BR BR112020008435-2A patent/BR112020008435A2/en unknown
- 2018-10-30 JP JP2020523711A patent/JP7229239B2/en active Active
- 2018-10-30 CN CN201880071243.0A patent/CN111295449B/en active Active
- 2018-10-30 EP EP18796626.2A patent/EP3704256A1/en not_active Withdrawn
- 2018-10-30 WO PCT/EP2018/079719 patent/WO2019086461A1/en not_active Ceased
- 2018-10-30 MX MX2020004490A patent/MX421606B/en unknown
- 2018-10-30 KR KR1020207014978A patent/KR102755022B1/en active Active
- 2018-10-30 EA EA202091039A patent/EA202091039A1/en unknown
- 2018-10-30 US US16/760,565 patent/US11459583B2/en active Active
- 2018-10-30 CA CA3077630A patent/CA3077630A1/en active Pending
- 2018-10-30 AU AU2018359494A patent/AU2018359494A1/en not_active Abandoned
-
2020
- 2020-04-26 IL IL274218A patent/IL274218A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019086461A1 (en) | 2019-05-09 |
| BR112020008435A2 (en) | 2020-11-17 |
| KR20200074988A (en) | 2020-06-25 |
| IL274218A (en) | 2020-06-30 |
| CN111295449B (en) | 2023-12-05 |
| EA202091039A1 (en) | 2020-08-10 |
| AU2018359494A1 (en) | 2020-04-23 |
| MX421606B (en) | 2025-03-14 |
| JP7229239B2 (en) | 2023-02-27 |
| MX2020004490A (en) | 2020-08-13 |
| JP2021500899A (en) | 2021-01-14 |
| CA3077630A1 (en) | 2019-05-09 |
| KR102755022B1 (en) | 2025-01-20 |
| CN111295449A (en) | 2020-06-16 |
| US20200347405A1 (en) | 2020-11-05 |
| US11459583B2 (en) | 2022-10-04 |
| EP3704256A1 (en) | 2020-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274218A (en) | Adenovirus vectors and uses thereof | |
| ZA202002184B (en) | Adenovirus and uses thereof | |
| ZA202002191B (en) | Adenovirus and uses thereof | |
| IL293377B1 (en) | Hsd17b13 variants and uses thereof | |
| IL273510A (en) | Combination therapies and uses thereof | |
| IL273236A (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| GB201713765D0 (en) | Modified adenovirus | |
| GB201715052D0 (en) | Vectors | |
| PL3265571T3 (en) | Multiple vector system and uses thereof | |
| IL274220A (en) | Adenovirus and uses thereof | |
| IL274278A (en) | Vectors | |
| GB201717524D0 (en) | Vectors | |
| IL269836B (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| GB201705927D0 (en) | Vector | |
| ZA201905513B (en) | Rorgamma modulators and uses thereof | |
| PT3250234T (en) | Recombinant mdv1 and the uses thereof | |
| IL275211A (en) | Fast and partition-resilient blockchains | |
| IL273671A (en) | Cornulin (crnn) variants and uses thereof | |
| ZA201905511B (en) | Rorgamma modulators and uses thereof | |
| IL269843B (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
| HK40026094A (en) | Adenovirus vectors and uses thereof | |
| HK40026092A (en) | Adenovirus and uses thereof | |
| HK40026097A (en) | Adenovirus and uses thereof | |
| HK40026096A (en) | Adenovirus and uses thereof | |
| GB201711971D0 (en) | Vectors |